File Download
  Links for fulltext
     (May Require Subscription)

Article: Coronavirus disease 2019 (COVID-19): latest developments in potential treatments

TitleCoronavirus disease 2019 (COVID-19): latest developments in potential treatments
Authors
Keywordscoronavirus
COVID-19
review
SARS-CoV-2
therapeutics
Issue Date2020
PublisherJUST Medical Media Ltd. The Journal's web site is located at http://drugsincontext.com/
Citation
Drugs in Context, 2020, v. 9, p. 1-14 How to Cite?
AbstractMany viral respiratory infections can cause severe acute respiratory symptoms leading to mortality and morbidity. In the spring of 2003, the severe acute respiratory syndrome (SARS) outbreak caused by SARS-CoV spread globally. In the summer of 2012, the Middle East respiratory syndrome (MERS) outbreak caused by MERS-CoV occurred in Saudi Arabia. In the winter of 2019, the coronavirus disease 2019 (COVID-19) outbreak caused by a novel coronavirus SARS-CoV- 2 occurred in China which rapidly spread worldwide causing a global pandemic. Up until 27 May 2020, there are 5.5 million confirmed cases of COVID-19 and 347,587 COVID-19 related deaths worldwide, and there has also been an unprecedented increase in socioeconomic and psychosocial issues related to COVID-19. This overview aims to review the current developments in preventive treatments and therapies for COVID-19. The development of vaccines for SARS-CoV-2 is ongoing and various clinical trials are currently underway around the world. It is hoped that existing antivirals including remdesivir and lopinavir-ritonavir might have roles in the treatment of COVID-19, but results from trials thus far have not been promising. COVID-19 causes a mild respiratory disease in the majority of cases, but in some cases, cytokine activation causes sepsis and acute respiratory distress syndrome, leading to morbidity and mortality. Immunomodulatory treatments and biologics are also being actively explored as therapeutics for COVID-19. On the other hand, the use of steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs) has been discouraged based on concerns about their adverse effects. Over the past two decades, coronaviruses have caused major epidemics and outbreaks worldwide, whilst modern medicine has been playing catch-up all along.
Persistent Identifierhttp://hdl.handle.net/10722/284590
ISSN
2015 SCImago Journal Rankings: 0.600

 

DC FieldValueLanguage
dc.contributor.authorHon, KL-
dc.contributor.authorLeung, KKY-
dc.contributor.authorLeung, AKC-
dc.contributor.authorQian, SY-
dc.contributor.authorChan, VPY-
dc.contributor.authorIp, P-
dc.contributor.authorWong, ICK-
dc.date.accessioned2020-08-07T08:59:48Z-
dc.date.available2020-08-07T08:59:48Z-
dc.date.issued2020-
dc.identifier.citationDrugs in Context, 2020, v. 9, p. 1-14-
dc.identifier.issn1745-1981-
dc.identifier.urihttp://hdl.handle.net/10722/284590-
dc.description.abstractMany viral respiratory infections can cause severe acute respiratory symptoms leading to mortality and morbidity. In the spring of 2003, the severe acute respiratory syndrome (SARS) outbreak caused by SARS-CoV spread globally. In the summer of 2012, the Middle East respiratory syndrome (MERS) outbreak caused by MERS-CoV occurred in Saudi Arabia. In the winter of 2019, the coronavirus disease 2019 (COVID-19) outbreak caused by a novel coronavirus SARS-CoV- 2 occurred in China which rapidly spread worldwide causing a global pandemic. Up until 27 May 2020, there are 5.5 million confirmed cases of COVID-19 and 347,587 COVID-19 related deaths worldwide, and there has also been an unprecedented increase in socioeconomic and psychosocial issues related to COVID-19. This overview aims to review the current developments in preventive treatments and therapies for COVID-19. The development of vaccines for SARS-CoV-2 is ongoing and various clinical trials are currently underway around the world. It is hoped that existing antivirals including remdesivir and lopinavir-ritonavir might have roles in the treatment of COVID-19, but results from trials thus far have not been promising. COVID-19 causes a mild respiratory disease in the majority of cases, but in some cases, cytokine activation causes sepsis and acute respiratory distress syndrome, leading to morbidity and mortality. Immunomodulatory treatments and biologics are also being actively explored as therapeutics for COVID-19. On the other hand, the use of steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs) has been discouraged based on concerns about their adverse effects. Over the past two decades, coronaviruses have caused major epidemics and outbreaks worldwide, whilst modern medicine has been playing catch-up all along.-
dc.languageeng-
dc.publisherJUST Medical Media Ltd. The Journal's web site is located at http://drugsincontext.com/-
dc.relation.ispartofDrugs in Context-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectcoronavirus-
dc.subjectCOVID-19-
dc.subjectreview-
dc.subjectSARS-CoV-2-
dc.subjecttherapeutics-
dc.titleCoronavirus disease 2019 (COVID-19): latest developments in potential treatments-
dc.typeArticle-
dc.identifier.emailIp, P: patricip@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.authorityIp, P=rp01337-
dc.identifier.authorityWong, ICK=rp01480-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.7573/dic.2020-4-15-
dc.identifier.scopuseid_2-s2.0-85090544759-
dc.identifier.hkuros311724-
dc.identifier.volume9-
dc.identifier.spage1-
dc.identifier.epage14-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats